Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD

Pieri, Margherita; Schaffner, R.; Pieri, L.; Prada, M. Da; Haefely, W.

doi:10.1016/0024-3205(78)90057-7

Cited by 35 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Behavioral studies also demonstrate that lisuride has DA agonist activity. For example, lisuride induces contralateral turning in rats with unilateral 6-hydroxydopamine-induced lesions of the nigrostriatal DA pathway (Pieri et al 1978 ), an effect that is consistent with direct activation of postsynaptic DA receptors. The effects of lisuride on locomotor activity are also similar to those of the DA agonist apomorphine and different from those of LSD (Adams and Geyer 1985 ).…”

Section: Discussionmentioning

confidence: 90%

LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor

Halberstadt

Geyer

2009

Psychopharmacology

View full text Add to dashboard Cite

Rationale Compounds that activate the 5-HT 2A receptor, such as lysergic acid diethylamide (LSD), act as hallucinogens in humans. One notable exception is the LSD congener lisuride, which does not have hallucinogenic effects in humans even though it is a potent 5-HT 2A agonist. LSD and other hallucinogens have been shown to disrupt prepulse inhibition (PPI), an operational measure of sensorimotor gating, by activating 5-HT 2A receptors in rats. Objective We tested whether lisuride disrupts PPI in male Sprague-Dawley rats. Experiments were also conducted to identify the mechanism(s) responsible for the effect of lisuride on PPI and to compare the effects of lisuride to those of LSD. Results Confirming a previous report, LSD (0.05, 0.1, and 0.2 mg/kg, s.c.) reduced PPI, and the effect of LSD was blocked by pretreatment with the selective 5-HT 2A antagonist MDL 11,939. Administration of lisuride (0.0375, 0.075, and 0.15 mg/kg, s.c.) also reduced PPI. However, the PPI disruption induced by lisuride (0.075 mg/kg) was not blocked by pretreatment with MDL 11,939 or the selective 5-HT 1A antagonist WAY-100635 but was prevented by pretreatment with the selective dopamine D 2 /D 3 receptor antagonist raclopride (0.1 mg/kg, s.c).Conclusions The effect of LSD on PPI is mediated by the 5-HT 2A receptor, whereas activation of the 5-HT 2A receptor does not appear to contribute to the effect of lisuride on PPI. These findings demonstrate that lisuride and LSD disrupt PPI via distinct receptor mechanisms and provide additional support for the classification of lisuride as a nonhallucinogenic 5-HT 2A agonist.

show abstract

Section: Discussionmentioning

confidence: 90%

LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor

Halberstadt

Geyer

2009

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Major discrepancies exist between drug effects on platelets and the inhibitory 5-HT receptors of those brain areas with a dense 5-HT innervation (raphe nuclei, amygdala, ventral lateral geniculate, optic tectum). In these areas cinanserin, cyproheptadine, methergoline, methysergide, lisurid and methiothepin, which acted as potent 5-HT antagonists in platelets, did not antagonize 5-HT, but rather acted like 5-HT (Born et al, 1972;Drummond & Gordon, 1975;Haigler & Aghajanian, 1977;Kehr 1977;Pieri et al, 1978). In the hippocampus, where the 5-HT terminals have a nonuniform distribution, the 5-HT receptors differed somewhat from those in platelets.…”

Section: Discussionmentioning

confidence: 99%

Shape Change of Blood Platelets—a Model for Cerebral 5‐hydroxytryptamine Receptors?

Gräf

Pletscher

1979

British J Pharmacology

View full text Add to dashboard Cite

In blood platelets of rabbits isolated by a stractan gradient and incubated in a protein‐poor medium, tryptamine, 5‐hydroxytryptamine (5‐HT) and derivatives, quipazine and mescaline caused a shape change. This shape change was inhibited by low concentrations of methysergide. The most potent antagonists of the 5‐HT‐induced shape change included ergoline derivatives and neuroleptic drugs, which showed high stereoselectivity. (‐f)‐Lysergic acid diethylamide ((+)‐LSD), psilocine and some N',N′‐dimethylated tryptamines acted as mixed agonist‐antagonists. The compounds found to be agonists or mixed agonist‐antagonists on platelets have previously been shown to act also as 5‐HT agonists in the central nervous system (CNS). With regard to 5‐HT antagonists, the 5‐HT receptors of platelets reacted differently from those described earlier in brain areas with dense 5‐hydroxytryptaminergic innervation, but showed similarities to 5‐HT receptors investigated previously in spinal cord, cerebral cortex and possibly reticular formation. It is concluded that platelets may be considered with caution as models for some, but not for all, 5‐HT receptors in the CNS.

show abstract

“…Several authors have described lisuride as a nonaddictive ergot derivative that stimulates postsynaptic dopamine receptors (Horowski and Wachtel 1976;Rosenfeld and Makman 1981;Uzumaki et al 1982;Schechter 1984;Cunningham et al 1987a). Historically, in low doses, lisuride has been shown to induce locomotor inhibition and contralateral circling in rats with 6-hydroxydopamine (6-OH-DA) unilateral lesions of the substantia nigra and, in higher doses, locomotor stimulation, stereotypies, mounting behavior, and signs of the "serotonin syndrome" (Horowski and Wachtel 1976;Fuxe et al 1978;Pieri et al 1978;Wachtel 1978;Sielbergeld and Hruska 1979;Marini et al 1981). Because dopamine antagonists reversed these behavioral effects, it was suggested early on that lisuride acts as a dopamine agonist (Horowski and Wachtel 1976;Wachtel 1978).…”

Section: Introductionmentioning

confidence: 97%

Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine 1A receptor-mediated behavioral effects overlap its other properties in rats

et al. 2002

View full text Add to dashboard Cite

show abstract

Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD

Cited by 35 publications

References 18 publications

LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor

LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor

Shape Change of Blood Platelets—a Model for Cerebral 5‐hydroxytryptamine Receptors?

Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine 1A receptor-mediated behavioral effects overlap its other properties in rats

Contact Info

Product

Resources

About